Basal Plasma Aldosterone Concentration Predicts Therapeutic Outcomes in Primary Aldosteronism

Aya Saiki,[1] Michio Otsuki,[1] Kosuke Mukai,[1] Reiko Hayashi,[1] Iichiro Shimomura,[1] Isao Kurihara,[2] Takamasa Ichijo,[3] Yoshiyu Takeda,[4] Takuyuki Katabami,[5] Mika Tsuiki,[6] Norio Wada,[7] Yoshihiro Ogawa,[8] Junji Kawashima,[9] Masakatsu Sone,[10] Nobuya Inagaki,[10] Takanobu Yoshimoto,[11,12] Ryuji Okamoto,[13] Katsutoshi Takahashi,[14] Hiroki Kobayashi,[15] Kouichi Tamura,[16] Kohei Kamemura,[17] Koichi Yamamoto,[18] Shoichiro Izawa,[19] Miki Kakutani,[20] Masanobu Yamada,[21] Akiyo Tanabe,[22] Mitsuhide Naruse,[6,23] and JPAS/JRAS Study Group

[1]Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; [2]Department of Endocrinology, Metabolism, and Nephrology, School of Medicine, Keio University, Tokyo, Japan; [3]Department of Endocrinology and Metabolism, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan; [4]Department of Internal Medicine, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan; [5]Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Japan; [6]Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; [7]Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan; [8]Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; [9]Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; [10]Department of Diabetes, Endocrinology, and Nutrition, Kyoto University, Kyoto, Japan; [11]Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University, Tokyo, Japan; [12]Department of Diabetes and Endocrinology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan; [13]Department of Cardiology, Mie University Hospital, Mie, Japan; [14]Division of Metabolism, Showa General Hospital, Tokyo, Japan; [15]Division of Nephrology, Hypertension, and Endocrinology, Nihon University School of Medicine, Tokyo, Japan; [16]Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan; [17]Department of Cardiology, Shinko Hospital, Kobe, Japan; [18]Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; [19]Department of Endocrinology and Metabolism, Tottori University Hospital, Yonago, Japan; [20]Department of Internal Medicine, Division of Diabetes, Endocrinology and Clinical Immunology, Hyogo College of Medicine, Hyogo, Japan; [21]Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan; [22]Division of Endocrinology, National Center for Global Health and Medicine, Tokyo, Japan; and [23]Endocrine Center, Ijinkai Takeda General Hospital, Kyoto, Japan

ORCiD numbers: 0000-0001-5947-8621 (M. Otsuki); 0000-0001-8261-2593 (N. Inagaki); 0000-0002-8067-398X (R. Okamoto); 0000-0002-0660-5372 (K. Tamura).

Purpose: Normal basal plasma aldosterone concentration (PAC) reflects mild aldosterone excess compared to high basal PAC. We previously reported lower risk for cardiovascular and cerebrovascular events in patients with primary aldosteronism (PA) and normal basal PAC (nPA) than in those with high basal PAC (hPA). However, the differences in therapeutic outcomes between nPA and hPA are unclear. The aim of this multi-institutional, retrospective cohort study was to determine the clinical significance of nPA to therapeutic outcomes, including adrenalectomy (ADX) and treatment with mineralocorticoid receptor antagonists (MRAs).

Methods: A total of 1146 patients with PA who were diagnosed and underwent adrenal venous sampling (AVS) between January 2006 and October 2016 were enrolled. The clinical parameters at baseline and after ADX or treatment with MRA were compared between the nPA and hPA groups.

Results: Significantly higher rates of absent clinical success (36.6 vs. 21.9%, $P = 0.01$) and absent biochemical success (26.4 vs. 5.2%, $P < 0.01$) were found for the nPA group than for the hPA group, respectively. Logistic regression analysis identified baseline PAC as a significant independent predictor of absent clinical success of ADX and MRAs.

Conclusions: Plasma aldosterone concentration at baseline was a significant and independent predictor of absent clinical success of ADX and MRA. Mineralocorticoid receptor antagonist treatment appeared to be a better therapeutic choice than ADX in the nPA group.

Primary aldosteronism (PA) is major cause of secondary hypertension [1, 2]. Since autonomous aldosterone hypersecretion induces a rise in blood pressure and direct damage to the myocardium and arterial wall, PA patients are at higher risk of cardiovascular and cerebrovascular (CCV) events than those with essential hypertension [3–5]. This difference in the risk of cardiovascular events is reversed by the management of aldosterone excess by either adrenalectomy (ADX) or treatment with mineralocorticoid receptor antagonists (MRAs) [6]. The outcome of treatment suggests that aldosterone excess plays an important role in cardiovascular risk. Previous studies showed that higher plasma aldosterone concentration (PAC) [7, 8], hypokalemia [8, 9], unilateral subtype [8], positive results on the saline infusion test [10], and positive results on various other confirmatory tests [11] were associated with the risk of CCV events in PA patients. These findings suggest that the hormonal intensity of aldosterone reflects a CCV event risk. A previous study reported that basal PAC was less than 15 ng/dL in 36% of 74 PA patients [12]. We also reported previously that patients with PA and normal basal PAC (<16 ng/dL) (nPA) had clinical features of mild aldosterone excess, such as low incidence of hypokalemia and less use of antihypertensive medications than PA patients with high basal PAC (≥16 ng/dL) (hPA) [7]. In addition, nPA was associated with lower risk of CCV events than hPA [7]. However, there is no information on the differences in therapeutic outcomes between nPA and hPA.

The aim of this cross-sectional retrospective study was to determine the clinical significance of nPA in terms of therapeutic outcomes, such as ADX or treatment with MRA.

1. Materials and Methods

A. Subjects

This study was conducted as part of the Japan Primary Aldosteronism Study (JPAS) with retrospective cross-sectional analysis. The nationwide PA registry in Japan was established at 28 centers. Patients with PA who were diagnosed and underwent adrenal venous sampling (AVS) between January 2006 and February 2018 were enrolled in this study. Patients eligible for JPAS were men and women aged 20 to 90 years. Patients whom the investigators judged unsuitable were excluded. The clinical characteristics, biochemical findings, results of confirmatory tests, imaging findings, results of AVS, treatment, surgical findings, and related follow-up data were collected electronically using the web-based registry system. System construction, data security, and maintenance of the registered data were outsourced to EPS Corporation (Tokyo, Japan).

The study was conducted using a valid data set of 2814 PA patients in February 2018. The PA patients with available data 1 year after ADX or treatment with MRA were selected. Of these, we excluded patients who had been treated with MRA at the time of diagnosis or after ADX and patients with suspected autonomous cortisol secretion defined by serum cortisol levels ≥ 3 µg/dL after 1 mg dexamethasone. Finally, 1146 patients in this study (nPA = 601, hPA = 545, Table 1) underwent ADX (n = 349) or were treated with MRA (n = 797) and included in this study (Fig. 1).

Table 1.   Baseline characteristics of the PA patients.

	Total (n = 1146)	nPA (n = 601)	hPA (n = 545)	P
Sex male/female (%, male)	558/588 (48.7%)	270/331 (44.9%)	288/257 (52.8%)	<0.01
Age (years)	54 (45–62)	56 (48–63)	52 (43–61)	<0.01
Duration of hypertension (years)	6 (2–13)	4 (1–11)	8 (3–14)	<0.01
Age of hypertension onset (years)	45 (37–52)	48 (40–55)	41 (35–49)	<0.01
Systolic blood pressure (mmHg)	141 (129–152)	141 (129–152)	141 (130–152)	0.77
Diastolic blood pressure (mmHg)	87 (78–96)	87 (78–95)	88 (79–96)	0.39
Defined daily dose of antihypertensive medications	1.0 (0.7–2.0)	1.0 (0.5–1.5)	1.5 (1.0–2.2)	<0.01
Body mass index (kg/m^2)	24.4 (21.9–27.5)	24.5 (21.8–27.3)	24.2 (21.9–27.6)	0.69
Diabetes mellitus	15.4%	16.0%	14.7%	0.54
Dyslipidemia	29.4%	31.0%	27.7%	0.23
Ever smoker	34.4%	33.1%	35.7%	0.37
Drinker	53.1%	50.1%	56.3%	<0.05
Serum potassium (mEq/L)	3.8 (3.4–4.0)	3.9 (3.7–4.1)	3.5 (3.1–3.9)	<0.01
Hypokalemia	40.1%	19.0%	63.4%	<0.01
eGFR (mL/min/1.73 m^2)	77.8 (66.5–90.3)	77.8 (67.7–90.2)	77.7 (64.9–90.6)	0.23
Proteinuria	12.2%	6.9%	18.0%	<0.01
Cardiovascular and cerebrovascular events	7.5%	6.0%	9.2%	<0.05
Plasma aldosterone concentration (ng/dL)	15.3 (10.9–23.5)	11.1 (8.9–13.1)	24.2 (19.1–35.9)	<0.01
Plasma renin activity (ng/mL/hr)	0.3 (0.2–0.5)	0.3 (0.2–0.5)	0.3 (0.2–0.5)	0.63
ARR (ng/dL)/(ng/mL/hr)	49.6 (29.3–103.0)	34.9 (22.8–60.0)	84.0 (41.8–189.0)	<0.01
Adrenal mass on CT	45.4%	33.0%	59.1%	<0.01
AVS LI ≤ 2/ 2 < LI ≤ 4/ 4 < LI	52.5%/17.1%/30.4%	69.9%/17.7%/12.5%	33.6%/16.5%/49.9%	<0.01
CLR < 1	35.5%	15.2%	57.6%	<0.01

Data are median (first and third quartile) values. Hypokalemia was considered present if serum potassium was < 3.5 mEq/L at the diagnosis of PA or a patient was taking a potassium supplement. Oral potassium was used in patients with hypokalemia. Estimated glomerular filtration rate was calculated using the following formula: estimated glomerular filtration rate (mL/min/1.73 m^2) = 194 × serum creatinine (-1.094) × age (-0.287) × 0.739 (if female). Proteinuria was defined as +, 2+, and 3 + protein in urinalyses. AVS was evaluated if cannulation was success (selectivity index > 5). The selectivity index was defined as cortisol concentration in the adrenal vein to that in the inferior vena cava. The LI was calculated by dividing the aldosterone to cortisol ratio on the dominant side by that on the nondominant side. The CLR was calculated by dividing the aldosterone to cortisol ratio on the nondominant side by that in the inferior vena cava. AVS data after ACTH stimulation were used for analysis in the present study. P value for differences between nPA vs. hPA.
Abbreviations: ARR, plasma aldosterone concentration/plasma renin activity ratio; AVS, adrenal venous sampling; CLR, contralateral ratio; CT, computed tomography; eGFR, estimate glomerular filtration rate; LI, lateralization index.

B. Diagnosis of PA

Primary aldosteronism was diagnosed according to the guidelines of the Japan Endocrine Society [1] and Japan Society of Hypertension [13]. Primary aldosteronism was diagnosed by positive case detection with a ratio of PAC (measured in ng/dL) to plasma renin activity (PRA) (measured in ng/mL/h) aldosterone-to-renin ratio (ARR) of > 20 and at least 1 positive result on 4 confirmatory tests, including the captopril-challenge test, the saline-infusion test, the furosemide-upright test, and the oral salt-loading test. Antihypertensive medications were usually changed to calcium channel blockers and/or α-adrenergic blockers, as appropriate, until the final diagnosis was established. The PA patients were classified into the nPA group (normal PAC [<16 ng/dL]) or the hPA group (high PAC [≥16 ng/dL]) by using the PAC level measured before any confirmatory test and in a supine position for more than 30 minutes to avoid the effect of the sitting position and potential interference from antihypertensive drugs [7]. The PA subtype was diagnosed based on an AVS with adrenocorticotropic hormone (cosyntropin) stimulation, a procedure that was described in detail previously [14]. Adrenal vein cannulation was considered successful if the selectivity index was > 5 [15]. The selectivity index was defined as the ratio of cortisol concentration in

PA (N=2814)
ARR >20 (ng/dL)/(ng/mL/hr) and at least one positive results of four confirmatory tests.
Positive criteria for confirmatory tests:
   Captopril-challenge test; ARR >20 (ng/dL)/(ng/mL/hr) after captopril administration.
   Saline-infusion test; PAC >6 ng/dL after saline infusion.
   Furosemide-upright test; PRA <2.0 ng/mL/hr after loading.
   Oral salt-loading test; Urinary aldosterone >8μg/day.

Excluded

Treated with MRA at the time of diagnosis or after ADX.
Autonomous cortisol secretion.
Available data a year after treatment.

N=1146
Classified into two groups by using the PAC level measured before any confirmatory test

nPA ; PAC<16 ng/dL
N=601

hPA ; PAC≥16 ng/dL
N=545

MRA treatment
N=522

Adrenalectomy
N=79

Adrenalectomy
N=270

MRA treatment
N=275

Figure 1. Classification strategy for primary aldosteronism with normal and high basal plasma aldosterone concentration.

the adrenal vein to that in the inferior vena cava. Unilateral subtype diagnosis of PA was defined as a lateralization index (LI) > 4. The LI was calculated by dividing the aldosterone-to-cortisol ratio on the dominant side by that on the nondominant side.

C. Assessment of Clinical and Biochemical Outcomes by International Consensus Criteria

Various clinical parameters measured at baseline and 1 year after ADX were compared between the nPA and hPA groups. Individual surgical outcomes were evaluated using the international consensus criteria of the Primary Aldosteronism Surgical Outcome (PASO) study, which included 6 outcomes (complete, partial, and absent success of clinical and biochemical outcomes) based on blood pressure, defined daily dose (DDD) of antihypertensive medications, plasma potassium, PAC, and PRA [16]. In addition, individual clinical outcomes following MRA treatment were based on blood pressure and DDD excluding MRA.

D. Laboratory Tests

Plasma aldosterone concentration and PRA were measured by commercially available kits. Plasma aldosterone concentration was determined by radioimmunoassay (SPAC-S Aldosterone Kit [17]; Fuji Rebio, Co., Tokyo, Japan) in 25 centers and chemiluminescent enzyme immunoassay (Accuraseed Aldosterone [18]; FUJIFILM Wako Pure Chemical, Co., Tokyo, Japan) in 3 centers. The reference ranges of PAC measured in the supine position were 3.0 to 15.9 ng/dL and 2.99 to 15.9 ng/dL, respectively. Plasma renin activity was measured by radioimmunoassay or enzyme immunoassay. The reference range of PRA in the supine position was 0.3 to 2.9 ng/mL/h (PRA radioimmunoassay kits [19]; Fuji Rebio, Co., Tokyo, Japan) in 15 centers, 0.2 to 2.3 ng/mL/h (PRA enzyme immunoassay kits [20]; Yamasa, Co., Choshi, Japan) in 9 centers, and 0.2 to 2.7 ng/mL/h (PRA radioimmunoassay kits [21]; Yamasa, Co., Choshi, Japan) in 3 centers. Plasma active renin concentration (ARC) was measured by chemiluminescent enzyme immunoassay in 1 center and the ARC value was used for analysis by converting to PRA. The reference range of ARC in the supine position was 2.5 to 21.0 pg/mL (Accuraseed Renin [Japanese patent number 2877222, monoclonal antibody 12-12 and 11–6]; Wako Pure Chemical, Co., Tokyo, Japan].

E. Statistical Analysis

Data were expressed as median values (interquartile rage [IQR]). Differences between 2 groups were analyzed by the Wilcoxon test for continuous variables and by the chi-square test for categorical variables. For paired data comparing baseline and post-treatment, paired t-tests for variables and a McNemar's test for categorical data were used. Logistic regression analysis was performed to identify independent predictors of absent success of ADX and MRA treatment. The variables of PAC at baseline, sex, age, duration of hypertension, DDD before treatment, BMI, smoking and eGFR were selected for analysis based on the results of previous studies [7, 22–25]. Statistical significance was defined at the $P < 0.05$ significance level. All statistical analyses were performed using JMP Pro software for Windows (ver0.14, SAS Institute, Cary, NC).

2. Results

A. Clinical Characteristics of nPA and hPA Patients at Baseline

The baseline clinical characteristics of nPA (n = 601) and hPA (n = 545) patients are shown in Table 1. Compared with the hPA group, the nPA group included older (56 vs. 52 years, $P < 0.01$) patients with a lower proportion of males (44.9% vs. 52.8%, $P < 0.01$) that had a shorter duration of hypertension (4 vs. 8 years, $P < 0.01$) and older age at onset of hypertension (48 vs. 41 years, $P < 0.01$). The DDD was smaller in the nPA group than in the hPA group (1.0 vs. 1.5, $P < 0.01$), but there was no significant difference in blood pressure between the 2 groups. Serum potassium level was higher (3.9 vs. 3.5, $P < 0.01$) and the prevalence of hypokalemia was lower (19.0 vs. 63.4%, $P < 0.01$) in the nPA group than in the hPA group. Adrenal masses were found on the CT in fewer patients (33.0 vs. 59.1%, $P < 0.01$), and the proportions of patients with high LI and contralateral ratio (CLR) were significantly lower in the nPA group than in the hPA group.

B. Comparison of Clinical Features at Baseline and 1-year Follow-up after ADX and MRA

Table 2 lists differences in the clinical features of patients in the nPA and hPA groups recorded at baseline and 1 year after ADX. Compared with the baseline, ADX significantly improved blood pressure, DDD, and hypokalemia in both groups at 1-year follow-up. Although the estimated glomerular filtration rate (eGFR) decreased significantly in both groups, the prevalence of proteinuria was significantly lower only in the hPA group ($P < 0.01$) but not the nPA group ($P = 0.06$). While PAC at 1 year after ADX did not change in the nPA group ($P = 0.70$), it decreased significantly in the hPA group ($P < 0.01$). Furthermore, ARR decreased significantly in both groups due to significant increases in PRA.

Table 3 shows the changes in several clinical parameters associated with MRA treatment. Compared with the baseline, blood pressure, DDD excluding MRA, serum potassium level and the prevalence of hypokalemia improved in both the nPA and hPA groups after MRA treatment. In contrast to ADX, MRA treatment was associated with significant decreases in eGFR and improvement in the prevalence of proteinuria in both groups. Furthermore, ARR decreased significantly in both the nPA and hPA groups due to increases in both PAC and PRA.

C. Comparison of ADX Therapeutic Outcomes Between nPA and hPA Groups Using International Consensus Criteria

The clinical success of surgical outcomes was evaluated based on the international consensus criteria [16] (Fig. 2A). The rate of absent clinical success was significantly higher in the nPA group (36.6%) than in the hPA group (21.9%, $P = 0.01$). Twenty-six nPA patients were classified as absent clinical success (age 54 [45–60] years; duration of hypertension,

Table 2. Clinical characteristics of the 349 PA patients with adrenalectomy.

	nPA (n = 79)				hPA (n = 270)			
	n	Baseline	After ADX	P	n	Baseline	After ADX	P
Systolic blood pressure (mmHg)	79	141 (130–153)	130 (120–140)	<0.01	270	141 (130–153)	126 (118–136)	<0.01
Diastolic blood pressure (mmHg)	79	87 (78–91)	82 (73–90)	<0.01	270	87 (80–96)	80 (74–87)	<0.01
Defined daily dose of antihypertensive medications	71	1.0 (0.5–2.0)	0.5 (0–1.3)	<0.01	251	1.8 (1.0–2.3)	0.5 (0–1.3)	<0.01
Serum potassium (mEq/L)	75	3.8 (3.4–4.0)	4.3 (4.1–4.6)	<0.01	244	3.3 (2.9–3.6)	4.4 (4.1–4.7)	<0.01
Hypokalemia	72	36.1%	0%	<0.01	233	84.6%	0.4%	<0.01
eGFR (mL/min/1.73 m^2)	75	78.7 (65.4–92.9)	67.1 (55.5–78.7)	<0.01	246	78.3 (64.6–91.6)	62.1 (47.4–74.5) *	<0.01
Proteinuria	36	19.4%	5.6%	0.06	143	23.1%	7.7%	<0.01
Plasma aldosterone concentration (ng/dL)	57	10.7 (8.9–13.1)	10.8 (7.6–13.5)	0.70	171	30.0 (21.5–44.9)	10.5 (7.8–13.7)	<0.01
Plasma renin activity (ng/mL/hr)	57	0.2 (0.1–0.4)	0.8 (0.4–1.5)	<0.01	162	0.3 (0.1–0.4)	1.5 (0.6–2.7) **	<0.01
ARR (ng/dL)/(ng/mL/hr)	57	44.0 (29.5–80.0)	12.3 (6.4–22.1)	<0.01	161	123.5 (64.0–226.5)	7.4 (4.3–14.9) **	<0.01

Data are median (first and third quartile) values. See Table 1 for abbreviations.
*nPA After ADX vs. hPA after ADX, P < 0.05. ** nPA After ADX vs. hPA after ADX, P < 0.01.

Table 3. Clinical characteristics of the 797 PA patients with MRA treatment.

		nPA (n = 522)				hPA (n = 275)		
	n	Baseline	After MRA	P	n	Baseline	After MRA	P
MRA equivalent potency total daily dose (mg)		-	50 (50–100)			-	100 (50–100) [††]	
Spironolactone total daily dose (mg)		-	25 (25–50)			-	50 (25–75) [††]	
Eplerenone total daily dose (mg)		-	50 (50–100)			-	100 (50–100) [††]	
Systolic blood pressure (mmHg)	522	141 (129–152)	130 (120–138)	<0.01	275	141 (130–152)	130 (123–140)	<0.01
Diastolic blood pressure (mmHg)	522	87 (78–96)	80 (74–87)	<0.01	275	88 (79–96)	82 (76–89) [†]	<0.01
Defined daily dose of antihypertensive medications excluding MRA	471	1.0 (0.5–1.5)	0.5 (0–1.0)	<0.01	250	1.3 (1.0–2.0)	1.0 (0.5–1.8) [††]	<0.01
Serum potassium (mEq/L)	487	4.0 (3.7–4.2)	4.2 (4.0–4.5)	<0.01	257	3.7 (3.4–4.0)	4.2 (4.0–4.5)	<0.01
Hypokalemia	472	16.5%	2.8%	<0.01	249	45.4%	8.4% [††]	<0.01
eGFR (ml/min/1.73 m^2)	488	77.2 (67.6–90.1)	70.8 (60.4–81.7)	<0.01	257	76.4 (65.2–87.9)	66.8 (56.8–78.8) [††]	<0.01
Proteinuria	329	6.7%	3.7%	0.01	165	16.4%	8.5%	0.02
Plasma aldosterone concentration (ng/dL)	330	11.0 (8.8–13.0)	20.2 (14.4–28.3)	<0.01	175	21.0 (17.6–25.7)	30.9 (21.8–43.0) [††]	<0.01
Plasma renin activity (ng/mL/hr)	324	0.3 (0.2–0.5)	1.0 (0.5–1.8)	<0.01	172	0.4 (0.2–0.6)	1.0 (0.4–2.1)	<0.01
ARR (ng/dL)/(ng/mL/hr)	324	31.8 (21.7–53.5)	20.8 (12.4–40.0)	<0.01	172	55.5 (34.4–104.4)	32.1 (16.6–71.3) [††]	<0.01

Data are median (first and third quartile) values. The MRA equivalent potency dose is a metric to allow consolidation of spironolactone and eplerenone doses into a single MRA potency. Spironolactone is considered twice as potent as eplerenone for this calculation; therefore, the dosing was calculated by multiplying spironolactone total daily dose by two and eplerenone total daily dose by one.

[†]nPA After MRA treatment vs. hPA after MRA treatment, $P < 0.05$. [††]nPA After MRA treatment vs. hPA after MRA treatment, $P < 0.01$.

Abbreviation: MRA, mineralocorticoid receptor antagonist. See Table 1 for additional abbreviations.

(A)   Clinical success (n=322)   p=0.04

nPA   32.4   31.0   36.6   n=71

hPA   37.1   41.0   21.9   n=251

0%   20%   40%   60%   80%   100%

■ Complete   ■ Partial   ■ Absent

(B)   Biochemical success (n=208)   p<0.01

nPA   71.7   1.9   26.4   n=53

hPA   84.5   10.3 5.2   n=155

0%   20%   40%   60%   80%   100%

■ Complete   ■ Partial   ■ Absent

Figure 2. Clinical and biochemical outcomes after adrenalectomy in patients with primary aldosteronism. Clinical (n = 322) **(A)** and biochemical (n = 208) **(B)** outcomes were assessed by the international consensus criteria. *P* values for comparisons of the proportions of the 3 groups (complete, partial, and absent).

10 years[3–17]; BMI 25.8 (22.5–28.3) kg/m^2; diabetes mellitus, 19.2%, dyslipidemia, 46.2%; ever a smoker, 40.0%). Although serum potassium (baseline 3.8 [3.0–4.0], post-ADX 4.3 [4.0–4.5], *P* < 0.01) and ARR (baseline 50.0 [33.8–81.5], post-ADX 16.6 [9.1–30.5], *P* < 0.01) significantly improved after ADX in this absent clinical success group, DDD was significantly higher after ADX (baseline 1.0 [0.6–1.9], post-ADX 1.3 [0.8–2.2], *P* = 0.02), and blood pressure showed no improvement (systolic blood pressure, baseline 142 [126–146] mmHg, post-ADX 139 [129–148] mmHg, *P* = 0.68), (diastolic blood pressure, baseline 86 [77–90] mmHg, post-ADX 89 [80–90] mmHg, *P* = 0.84). Next, we evaluated the independent predictors of absent clinical success after ADX (Table 4). Univariate analysis showed that PAC at baseline, sex, duration of hypertension, BMI, smoking, and eGFR at baseline were significantly associated with absent clinical success after ADX. The above factors were entered into logistic regression analysis, and the results identified PAC at baseline, male sex, long duration of hypertension, and DDD as significant and independent predictors of absent clinical success after ADX.

With regards to the biochemical success of surgical outcomes, a significantly lower rate of complete biochemical success (71.7 vs. 84.5%, *P* = 0.04) and higher absent biochemical success (26.4 vs. 5.2%, *P* < 0.01) were noted in the nPA group than in the hPA group based on the international consensus criteria [16] (Fig. 2B).

D. Comparison of MRA Outcomes Between nPA and hPA Groups

The clinical parameters at baseline and after MRA treatment for PA patients are shown in Table 3. The MRA equivalent potency total daily dose and DDD excluding MRA was significantly smaller in the nPA group than in the hPA group (50 [50–100] vs. 100 [50–100] mg/day; *P* < 0.01, 0.5 [0–1.0] vs. 1.0 [0.5–1.8], *P* < 0.01, respectively). However, the post-MRA diastolic blood pressure and the prevalence of post-MRA hypokalemia were significantly lower in the nPA group (80 [74–87] vs. 82 [76–89] mmHg; *P* < 0.01, 2.8% vs. 8.4%, *P* < 0.01, respectively) than in the hPA group. Although eGFR was higher in the nPA group (70.8 [60.4–81.7] vs. 66.8 [56.8–78.8], *P* < 0.01) than in the hPA group, there was no difference in eGFR (baseline, post-MRA) between the 2 groups (nPA 7.1 vs. hPA 8.2 mL/min/1.73 m^2, *P* = 0.17).

Table 4. Results of logistic regression analysis of the 8 factors associated with absent clinical success after adrenalectomy.

Variable	Unadjusted Analysis		Adjusted Analysis	
	Odds ratio (95% CI)	P	Odds ratio (95% CI)	P
Plasma aldosterone concentration at baseline (ng/dL)	0.98 (0.97–0.99)	<0.01	0.97 (0.96–0.99)	<0.01
Plasma aldosterone concentration at baseline (ng/dL) IQR	0.77 (0.65–0.93)	<0.01	0.71 (0.57–0.89)	<0.01
Sex, male	2.99 (1.72–5.18)	<0.01	3.22 (1.55–6.69)	<0.01
Age (years) IQR	1.29 (0.89–1.87)	0.18	0.92 (0.53–1.58)	0.76
Duration of hypertension (years) IQR	1.49 (1.07–2.06)	0.02	1.77 (1.11–2.81)	0.02
Defined daily dose of antihypertensive medications before adrenalectomy IQR	0.93 (0.70–1.25)	0.65	0.62 (0.42–0.92)	0.02
Body mass index (kg/m^2) IQR	1.83 (1.30–2.58)	<0.01	1.30 (0.84–2.00)	0.24
Ever smoker	2.11 (1.24–3.61)	<0.01	1.79 (0.96–3.36)	0.07
eGFR before adrenalectomy (ml/min/1.73 m^2) IQR	0.67 (0.50–0.90)	<0.01	0.81 (0.55–1.18)	0.27

See Table 1 for abbreviations.

Clinical success (n=721)   p<0.01

Figure 3. Clinical outcomes after treatment with mineralocorticoid receptor antagonists in patients with primary aldosteronism. Clinical outcomes (n = 721) were assessed by the international consensus criteria. *P* values for comparisons of the proportions of the 3 groups (complete, partial, and absent).

Although the original international consensus criteria [16] were designed to assess surgical outcomes in unilateral PA, we adopted clinical success defined by these criteria based on blood pressure plus the use of antihypertensive drugs, excluding MRA for evaluation of the MRA therapeutic outcomes. The rate of complete success was higher and the rate of absent success was lower in the nPA group than in the hPA group (30.2% vs. 14.0%, *P* < 0.01 and 40.6% vs. 50.4%, *P* = 0.01, respectively, Fig. 3). As mentioned above, the MRA equivalent potency total daily dose and DDD excluding MRA was significantly smaller in the nPA group than in the hPA group (Table 3). We also evaluated the independent predictors of absent clinical success after MRA treatment (Table 5). Univariate analysis showed that PAC at baseline, male sex, duration of hypertension, and BMI were significantly associated with absent clinical success after MRA treatment. Logistic regression analysis of the above parameters identified PAC at baseline, male sex, long duration of hypertension, DDD, and BMI as significant independent predictors of absent clinical success after MRA treatment.

We also investigated clinical outcomes in 58 unilateral PA patients treated with MRA who did not undergo ADX. Even in these PA patients, the MRA equivalent potency total daily dose was lower in the nPA group than in the hPA group (50 [50–100] vs. 100 [50–100] mg/day, *P* < 0.01), and the clinical outcome tended to be better with nPA than with hPA (complete + partial 60.9, absent 39.1 vs. complete + partial 40.0%, absent 60.0%, *P* = 0.12).

Table 5. Results of logistic regression analysis for the factors associated with absent clinical success after treatment with mineralocorticoid receptor antagonists.

Variable	Unadjusted Analysis		Adjusted Analysis	
	Odds ratio (95% CI)	*P*	Odds ratio (95% CI)	*P*
Plasma aldosterone concentration at baseline (ng/dL)	1.02 (1.00–1.04)	<0.01	1.03 (1.00–1.05)	0.02
Plasma aldosterone concentration at baseline (ng/dL) IQR	1.31 (1.05–1.63)	<0.01	1.37 (1.04–1.79)	0.02
Sex, male	1.83 (1.36–2.46)	<0.01	1.66 (1.16–2.38)	<0.01
Age (years) IQR	0.89 (0.71–1.13)	0.35	0.93 (0.67–1.28)	0.66
Duration of hypertension (years) IQR	1.36 (1.13–1.65)	<0.01	1.48 (1.17–1.86)	<0.01
Defined daily dose of antihypertensive medications before MRA IQR	0.90 (0.74–1.09)	0.28	0.62 (0.48–0.80)	<0.01
Body mass index (kg/m^2) IQR	1.31 (1.07–1.61)	<0.01	1.39 (1.09–1.76)	<0.01
Ever smoker	1.27 (0.91–1.76)	0.15	1.06 (0.73–1.54)	0.76
eGFR before MRA (ml/min/1.73 m^2) IQR	1.11 (0.92–1.35)	0.28	1.14 (0.89–1.45)	0.30

See Table 1 for abbreviations.

3. Discussion

The main findings of the present study suggested that MRA treatment was a better therapeutic choice than ADX in nPA patients. Our study also showed that PAC at baseline was a significant and independent predictor of absent clinical success after both ADX and MRA treatment.

Previous studies reported that the cure rate of hypertension (blood pressure < 140/90 mmHg without medication) in PA after ADX ranged from 37% to 42% [16, 25]. In our study, the cure rate of hypertension in 349 PA patients (including 79 nPA and 270 hPA patients) by ADX was 36.0%. Interestingly, the rate of absent clinical success was significantly higher in nPA patients than in those with hPA. The results demonstrated that it might be difficult for nPA patients to achieve normotension after ADX without medication. Other investigators identified several predictors of the resolution of hypertension in PA patients after ADX. These include shorter duration of hypertension [22, 23, 26], fewer drug classes [22, 23, 26, 27], younger age [24, 26], female sex [22, 26, 27], lower BMI [26, 27], larger tumor size [24], lower eGFR [23], and a negative medical history of diabetes [26]. In the present study, we found that lower PAC was a significant predictor of absent clinical success with the lack of blood pressure normalization after ADX. On the other hand, Zhang et al [28] reported that higher PAC (≥35 ng/dL) was associated with a lower hypertension cure rate after surgery, probably because high PAC may induce irreversible cardiovascular remodeling.

Treatment with MRA (spironolactone and eplerenone) is recommended for PA patients with the bilateral subtype or who are unwilling to undergo surgery [29–31]. Our results suggest that nPA was a mild type of PA because the nPA group included a larger proportion of patients who showed complete clinical success than that of the hPA group, and the MRA equivalent potency total daily dose and DDD excluding MRA was significantly lower in the nPA group than in the hPA group after MRA treatment.

Absent biochemical success after ADX reflects a failure in PA treatment. One of the causes of such a failure is misdiagnosis of the PA subtype by AVS [32]. However, there were no significant differences in AVS results (rate of LR > 4 and CLR < 1) between absent biochemical success and complete + partial biochemical success groups (56.3 vs. 72.6%, *P* = 0.17).

The PA patients with absent biochemical success had higher serum potassium (3.8 [3.5–4.3] vs. 3.4 [3.0–3.7] mEq/L, *P* < 0.01) and smaller DDD (1.0 [0–1.8] vs. 1.3 [1.0–2.3], *P* < 0.01] at baseline than those in the complete + partial biochemical success group. Although the PRA levels at baseline were similar in the nPA and hPA groups, the level was significantly

lower in the nPA group than in the hPA group after ADX. These results suggest that nPA might involve other factors that can suppress PRA rather than PAC excess. For example, a high salt diet, aging [33], drugs known to interfere with the renin-angiotensin-aldosterone system, and a reduction in the nephron population are known factors involved in low-renin essential hypertension [34, 35]. Another reason for this result could be due to asymmetrical bilateral PA that was detected at AVS as unilateral.

The interpretation of the results of this study might be limited by its retrospective design. Adrenal venous sampling with adrenocorticotropic hormone (cosyntropin) stimulation improves AVS, but it hides the lateralization of aldosterone excess in some cases. Further prospective studies are needed to confirm the clinical significance of nPA on therapeutic outcomes, including ADX and MRA treatment.

In conclusion, we have demonstrated in the present study the importance of PAC at baseline as a predictor of clinical and biochemical success as assessed by the international consensus criteria of ADX and MRA treatment. The results also showed that MRA treatment may be a better therapeutic strategy with regards to clinical outcomes than ADX in patients with normal basal PAC.

Acknowledgments

Additional Information

Correspondence: Michio Otsuki, MD, PhD, Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565–0871, Japan. Phone: +81-6-6879-3732. Fax: +81-6-6879-3739. E-mail: otsuki@endmet.med.osaka-u.ac.jp.

Disclosure Summary: The authors declare no conflicts of interest.

References

1. Nishikawa T, Omura M, Satoh F, et al.; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism–the Japan Endocrine Society 2009. *Endocr J.* 2011;**58**(9):711–721.

2. Funder JW, Carey RM, Fardella C, et al.; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2008;**93**(9):3266–3281.

3. Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* 2018;**6**(1):41–50.

4. Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. *J Clin Endocrinol Metab.* 2013;**98**(12):4826–4833.

5. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol.* 2005;**45**(8):1243–1248.

6. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. *Arch Intern Med.* 2008;**168**(1):80–85.

7. Murata M, Kitamura T, Tamada D, et al. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. *J Hypertens.* 2017;**35**(5):1079–1085.

8. Ohno Y, Sone M, Inagaki N, et al.; Nagahama Study; JPAS Study Group. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. *Hypertens.* 2018;**71**(3):530–537.

9. Born-Frontsberg E, Reincke M, Rump LC, et al.; Participants of the German Conn's Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. *J Clin Endocrinol Metab.* 2009;**94**(4):1125–1130.

10. Hayashi R, Tamada D, Murata M, et al. Saline Infusion Test highly associated with the incidence of cardio- and cerebrovascular events in primary aldosteronism. *Endocr J.* 2017;**64**(5):507–513.

11. Saiki A, Tamada D, Hayashi R, et al. The number of positive confirmatory tests is associated with the clinical presentation and incidence of cardiovascular and cerebrovascular events in primary aldosteronism. *Hypertens Res.* 2019;**42**(8):1186–1191.

12. Stowasser M, Gordon RD. Primary aldosteronism–careful investigation is essential and rewarding. *Mol Cell Endocrinol.* 2004;**217**(1-2):33–39.

13. Shimamoto K, Ando K, Fujita T, et al.; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). *Hypertens Res.* 2014;**37**(4):253–390.

14. Umakoshi H, Wada N, Ichijo T, et al.; WAVES-J Study Group. Optimum position of left adrenal vein sampling for subtype diagnosis in primary aldosteronism. *Clin Endocrinol (Oxf).* 2015;**83**(6):768–773.

15. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. *Surg.* 2004;**136**(6):1227–1235.

16. Williams TA, Lenders JWM, Mulatero P, et al.; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. *Lancet Diabetes Endocrinol.* 2017;**5**(9):689–699.

17. RRID. AB_2801309, https://scicrunch.org/resolver/AB_2801309.

18. RRID. CVCL_D151, https://scicrunch.org/resources/Any/search?q=CVCL-D151&l=CVCL-D151.

19. RRID. AB_2801311, https://scicrunch.org/resolver/AB_2801311.

20. RRID. AB_2801275, https://scicrunch.org/resolver/AB_2801275.

21. RRID. AB_2801312, https://scicrunch.org/resolver/AB_2801312.

22. Zarnegar R, Young WF Jr, Lee J, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. *Ann Surg.* 2008;**247**(3):511–518.

23. Waldmann J, Maurer L, Holler J, et al. Outcome of surgery for primary hyperaldosteronism. *World J Surg.* 2011;**35**(11):2422–2427.

24. Pang TC, Bambach C, Monaghan JC, et al. Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. *ANZ J Surg.* 2007;**77**(9):768–773.

25. Steichen O, Zinzindohoué F, Plouin PF, Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. *Horm Metab Res.* 2012;**44**(3):221–227.

26. Morisaki M, Kurihara I, Itoh H, et al.; JPAS Study Group. Predictors of clinical success after surgery for primary aldosteronism in the Japanese Nationwide Cohort. *J Endocr Soc.* 2019;**3**(11):2012–2022.

27. Carter Y, Roy M, Sippel RS, Chen H. Persistent hypertension after adrenalectomy for an aldosterone-producing adenoma: weight as a critical prognostic factor for aldosterone's lasting effect on the cardiac and vascular systems. *J Surg Res.* 2012;**177**(2):241–247.

28. Zhang X, Zhu Z, Xu T, Shen Z. Factors affecting complete hypertension cure after adrenalectomy for aldosterone-producing adenoma: outcomes in a large series. *Urol Int.* 2013;**90**(4):430–434.

29. Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. *Expert Opin Pharmacother.* 2008;**9**(4):509–515.

30. Karashima S, Yoneda T, Kometani M, et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. *Hypertens Res.* 2016;**39**(3):133–137.

31. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2016;**101**(5):1889–1916.

32. Yang Y, Reincke M, Williams TA. Treatment of unilateral PA by adrenalectomy: potential reasons for incomplete biochemical cure. *Exp Clin Endocrinol Diabetes.* 2019;**127**(2-03):100–108.

33. Nakama C, Kamide K, Kawai T, et al. The influence of aging on the diagnosis of primary aldosteronism. *Hypertens Res.* 2014;**37**(12):1062–1067.

34. Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension. *Clin Endocrinol (Oxf).* 2007;**67**(3):324–334.

35. Monticone S, Losano I, Tetti M, Buffolo F, Veglio F, Mulatero P. Diagnostic approach to low-renin hypertension. *Clin Endocrinol (Oxf).* 2018;**89**(4):385–396.